PRECISELY Targeted Therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
We are passionate about using our expertise to address the needs of patients with cancer.
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial ResultsRead More >
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023Read More >
Nuvalent to Participate in the 43rd Annual Cowen Healthcare ConferenceRead More >
Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare ConferenceRead More >